Immuneering Co. (NASDAQ:IMRX) Receives $12.20 Average Target Price from Analysts

Shares of Immuneering Co. (NASDAQ:IMRX) have earned an average rating of “Hold” from the seven ratings firms that are covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and three have issued a buy rating on the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $9.00.

Several equities research analysts have recently weighed in on the stock. Needham & Company LLC reaffirmed a “buy” rating and issued a $12.00 price target on shares of Immuneering in a research report on Thursday, February 6th. Chardan Capital restated a “buy” rating and set a $13.00 target price on shares of Immuneering in a report on Wednesday, January 8th. Finally, Morgan Stanley downgraded Immuneering from an “equal weight” rating to an “underweight” rating in a report on Friday, December 13th.

Immuneering Price Performance

IMRX stock opened at $1.51 on Friday. Immuneering has a 1-year low of $1.00 and a 1-year high of $6.78. The business has a 50-day moving average price of $1.93 and a 200 day moving average price of $1.95. The company has a market capitalization of $46.89 million, a P/E ratio of -0.77 and a beta of -0.36.

Hedge Funds Weigh In On Immuneering

Large investors have recently made changes to their positions in the business. HighTower Advisors LLC boosted its position in shares of Immuneering by 21.4% in the 3rd quarter. HighTower Advisors LLC now owns 53,360 shares of the company’s stock worth $132,000 after purchasing an additional 9,400 shares in the last quarter. Corsair Capital Management L.P. acquired a new stake in Immuneering in the third quarter worth about $25,000. Southport Management L.L.C. grew its stake in shares of Immuneering by 4.9% during the fourth quarter. Southport Management L.L.C. now owns 215,000 shares of the company’s stock worth $473,000 after acquiring an additional 10,000 shares during the last quarter. Two Sigma Investments LP increased its holdings in shares of Immuneering by 25.0% during the fourth quarter. Two Sigma Investments LP now owns 50,557 shares of the company’s stock valued at $111,000 after acquiring an additional 10,126 shares in the last quarter. Finally, Tang Capital Management LLC purchased a new position in shares of Immuneering in the 4th quarter valued at approximately $27,000. 67.65% of the stock is owned by institutional investors and hedge funds.

About Immuneering

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors.